Key Highlights

  • Alnylam Pharmaceuticals shares are trading at $234.81 in Thursday's session, down 4.84%.
  • Investors are weighing the outlook for the ATTR-CM franchise, with the stock down roughly 18% from earlier levels.
  • First-half 2026 net product Revenue reached $2.21 billion, up 94%.
  • A brokerage kept an Overweight rating but trimmed its price target to $369.

ATTR-CM Worries Pressure the Stock

Alnylam Pharmaceuticals (NASDAQ:ALNY) is falling in Thursday's session as investors keep weighing the outlook for its ATTR-CM Franchise following a failed trial from AstraZeneca (NYSE:AZN) and a partner in the same disease area. The Cambridge, Massachusetts-based company pioneered RNA interference therapeutics, and its approved therapies include Onpattro, Amvuttra, Givlaari, Oxlumo and Leqvio.

The shares are down about 5% at $234.81, roughly 18% below earlier levels and well under the 52-week high of $495.55. No new company announcement has been identified, and the wider healthcare sector is steadier.

Fundamentals Look Strong Beside the Share Price

First-half 2026 net product revenue came to $2.21 billion, up 94%. Alnylam also launched an Amvuttra ATTR-CM awareness campaign this week.

Analysts Stay Constructive but Trim Targets

Some analysts remain positive, with one placing Fair Value near $392 and citing nucresiran's TTR knockdown and Amvuttra's first-line share gains. Another brokerage kept an Overweight rating but trimmed its price target to $369.

October Huntington's Data Is the Next Catalyst

Investors are looking ahead to October data for ALN-HTT02 in Huntington's disease. The stock trades within a 52-week range of $197.81 to $495.55.